Cita APA

F, P., C, C., JA, S., M, C., C, C., MA, G., . . . M, C. (2025). Cost-effectiveness analysis of subcutaneous biosimilar tocilizumab in patients with rheumatoid arthritis in Spain.

Citación estilo Chicago

F, Pérez-Ruiz, Crespo-Diz C, Schoenenberger-Arnaiz JA, Cerezales M, Crespo C, Guigini MA, Peinado-Fabregat JI, y Climente-Martí M. Cost-effectiveness Analysis of Subcutaneous Biosimilar Tocilizumab in Patients With Rheumatoid Arthritis in Spain. 2025.

Cita MLA

F, Pérez-Ruiz, et al. Cost-effectiveness Analysis of Subcutaneous Biosimilar Tocilizumab in Patients With Rheumatoid Arthritis in Spain. 2025.